Issue 22 of Multiple Myeloma Research Review.
Highlights include:
• Benefits of low dose lenalidomide in relapsed/refractory MM.
• Network meta-analysis: treatment outcomes in relapsed/refractory MM.
• Improved outcomes for patients treated a speciality MM clinics.
• Real world benefits of bortezomib regimens for non-transplant eligible MM.